Nucleic acid delivery with α-tocopherol-Polyethyleneimine-Polyethylene glycol nanocarrier system

A K M Nawshad Hossian¹, Seetharama Jois¹, Subash C. Jonnalagadda² and George Mattheolabakis^{1*}

¹School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA;²Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ

Supplementary information

Supplementary Figure 1: Representative size and zeta potential measurement of TPP₁₁₁ in HEPES buffer using DLS.



Supplementary Figure 2: Cell viability assay for PEI-1800 in A549 cells at 24, 48 and 72 h of incubation.



Time points	IC ₅₀
24 h	278.3 μg/ml
48 h	213.1 μg/ml
72 h	100.2 μg/ml

Supplementary Figure 3: The transfection of TPP₁₁₁ polymer complexed with pGL-3 luciferase-expressing plasmid was evaluated in H358 cells at 24, 48 and 72 h time points, using different N/P ratios; x-axis values indicate the P in the N/P ratio; #: p < 0.05; ##: p < 0.01; ###:p < 0.001. All statistical analyses are two-tailed t-tests compared to pGL-3 alone.



Supplementary Figure 4: Cellular uptake analysis of Cy-5.5-conjugated TPP₁₁₁ complexed with pGL-3 plasmid was detected in H358 cells using Confocal Laser Scanning Microscopy (CLSM), potentiated by endosomal uptake. Lysosomes and endosomes were stained with Red DND-99 (sudo color green) and GFP (green), respectively. Nuclei (blue) were stained with DAPI. H358 cells were incubated with TPP₁₁₁-plasmid complexes for different incubation periods. The scale bar is at 40 µm. Co-localization of TPP₁₁₁-plasmid complexes and endosomes/lysosomes is indicated with white arrows.

	DAPI	Endo tracker	Lyso tracker	TPP	DAPI-Endo-TPP	DAPI-Lyso-TPP
Control	фо 10 ин	e e e e e e e e e e e e e e e e e e e	ССС			
30min				S.S.		
1h			200			
2h	Kur -			- фи		
4h		- Arr	•	- 6,5		i du
6h	алана ал	, ₂ Ba	. v .29	يد ته هدر	ະ ູຼ. • •	يني ^ت ر هذر
	40 um	40 um	40 um	40 um	40 um	40 um

Supplementary Figure 5: In vivo organ biodistribution of Cy5.5 conjugated TPP₁₁₁ complexed with PGL3 plasmid, following i.v. administration, at different time points.



×10⁸

Heart Lung Spleen Kidneys Tumors Brain